Kolawole Michael Odutola

Dr. Kolawole Michael Odutola

UNSW Sydney, Sydney, New South Wales, Australia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Global Health Action
Verified
Journal Article
Open access
SASally N. Adebamowo
Sally N. Adebamowo
VFVeronica Francis
Veronica Francis
ETErnest Tambo
Ernest Tambo
SDSeybou H. Diallo
Seybou H. Diallo
GLGuida Landouré
Guida Landouré
NNNicholas Ngomi
Nicholas Ngomi
Background: There is exponential growth in the interest and implementation of genomics research in Africa. This growth has been facilitated by the Human Hereditary and Health in Africa (H3Africa) initiative, which aims to promote a contemporary research approach to the study of genomics and environmental determinants of common diseases in African populations. Objective: The purpose of this article is to describe important challenges affecting genomics research implementation in Africa. Methods: The observations, challenges and recommendations presented in this article were obtained through discussions by African scientists at teleconferences and face-to-face meetings, seminars at consortium conferences and in-depth individual discussions. Results: Challenges affecting genomics research implementation in Africa, which are related to limited resources include ill-equipped facilities, poor accessibility to research centers, lack of expertise and an enabling environment for research activities in local hospitals. Challenges related to the research study include delayed funding, extensive procedures and interventions requiring multiple visits, delays setting up research teams and insufficient staff training, language barriers and an underappreciation of cultural norms. While many African countries are struggling to initiate genomics projects, others have set up genomics research facilities that meet international standards. Conclusions: The lessons learned in implementing successful genomics projects in Africa are recommended as strategies to overcome these challenges. These recommendations may guide the development and application of new research programs in low-resource settings.

13 April 2017 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
SASally N Adebamowo
Sally N Adebamowo
EDEileen O Dareng
Eileen O Dareng
AFAyotunde O Famooto
Ayotunde O Famooto
RORichard Offiong
Richard Offiong
OOOlayinka Olaniyan
Olayinka Olaniyan
CAClement A Adebamowo
Clement A Adebamowo
Globally, cervical cancer is the fourth most common cancer among women, with an estimated 528 000 new cases in 2012. 1 Although it remains a significant public health problem worldwide, the burden of cervical cancer falls disproportionately on low-resource countries. In the USA, the incidence rate of cervical cancer was 6.6 per 100 000 in 2012, 1 compared with 23.0 per 100 000 in Nigeria 2 which had about half the population of the USA in 2012.

30 July 2015 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
EJElima E. Jedy-Agba
Elima E. Jedy-Agba
EOEmmanuel Oga
Emmanuel Oga
KOKolawole Michael Odutola
Kolawole Michael Odutola
YAYusuf M. Abdullahi
Yusuf M. Abdullahi
APAbiodun Popoola
Abiodun Popoola
CAClement A. Adebamowo
Clement A. Adebamowo
The epidemiologic transition in sub-Saharan Africa (SSA) has given rise to a concomitant increase in the incidence of non-communicable diseases including cancers. Worldwide, cancer registries have been shown to be critical for the determination of cancer burden, conduct of research, and in the planning and implementation of cancer control measures. Cancer registration though vital is often neglected in SSA owing to competing demands for resources for healthcare. We report the implementation of a system for representative nation-wide cancer registration in Nigeria - the Nigerian National System of Cancer Registries (NSCR). The NSCR coordinates the activities of cancer registries in Nigeria, strengthens existing registries, establishes new registries, complies and analyses data, and makes these freely available to researchers and policy makers. We highlight the key challenges encountered in implementing this strategy and how they were overcome. This report serves as a guide for other low and middle income countries (LMIC) wishing to expand cancer registration coverage in their countries and highlights the training, mentoring, scientific and logistic support, and advocacy that are crucial to sustaining cancer registration programs in LMIC

7 January 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EDEileen O. Dareng
Eileen O. Dareng
SASally N. Adebamowo
Sally N. Adebamowo
AFAyotunde Famooto
Ayotunde Famooto
OOOluwatoyosi Olawande
Oluwatoyosi Olawande
KOKolawole Michael Odutola
Kolawole Michael Odutola
CAClement A. Adebamowo
Clement A. Adebamowo
Genital warts are important causes of morbidity and their prevalence and incidence can be used to evaluate the impact of HPV vaccination in a population. We enrolled 1020 women in a prospective cohort study in Nigeria and followed them for a mean (SD) of 9 (4) months. Nurses conducted pelvic examinations and collected ectocervical samples for HPV testing. We used exact logistic regression models to identify risk factors for genital warts. The mean age of study participants was 38 years, 56% (535/962) were HIV-negative and 44% (427/962) were HIV-positive. Prevalence of genital warts at enrolment was 1% (4/535) among HIV-negative women, and 5% (23/427) among HIV-positive women. Of 614 women (307 HIV negative and 307 HIV positive women) for whom we could compute genital wart incidence, it was 515 (95% CI:13–2872) per 100,000 person-years in HIV-negative and 1370 (95% CI:283–4033) per 100,000 person-years in HIV-positive women. HIV was associated with higher risk of prevalent genital warts (OR:7.14, 95% CI:2.41–28.7, p < 0.001) while higher number of sex partners in the past year was associated with increased risk of incident genital warts (OR:2.86, 95% CI:1.04–6.47. p = 0.04). HPV11 was the only HPV associated with prevalent genital warts in this population (OR:8.21, 95% CI:2.47–27.3, p = 0.001). Genital warts are common in Nigeria and our results provide important parameters for monitoring the impact of future HPV vaccination programs in the country. HIV infection and number of sexual partners in past year were important risk factors for prevalent and incident genital warts respectively.

11 May 2016 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
EOEmmanuel Oga
Emmanuel Oga
JBJessica P. Brown
Jessica P. Brown
CBClayton Brown
Clayton Brown
EDEileen Dareng
Eileen Dareng
VAVictor Adekanmbi
Victor Adekanmbi
CAClement Adebamowo
Clement Adebamowo
The burden of cervical cancer remains huge globally, more so in sub-Saharan Africa. Effectiveness of screening, rates of recurrence following treatment and factors driving these in Africans have not been sufficiently studied. The purpose of this study therefore was to investigate factors associated with recurrence of cervical intraepithelial lesions following thermo-coagulation in HIV-positive and HIV-negative Nigerian women using Visual Inspection with Acetic Acid (VIA) or Lugol’s Iodine (VILI) for diagnosis. A retrospective cohort study was conducted, recruiting participants from the cervical cancer “see and treat” program of IHVN. Data from 6 sites collected over a 4-year period was used. Inclusion criteria were: age ≥18 years, baseline HIV status known, VIA or VILI positive and thermo-coagulation done. Logistic regression was performed to examine the proportion of women with recurrence and to examine factors associated with recurrence. Out of 177 women included in study, 67.8 % (120/177) were HIV-positive and 32.2 % (57/177) were HIV-negative. Recurrence occurred in 16.4 % (29/177) of participants; this was 18.3 % (22/120) in HIV-positive women compared to 12.3 % (7/57) in HIV-negative women but this difference was not statistically significant (p-value 0.31). Women aged ≥30 years were much less likely to develop recurrence, adjusted OR = 0.34 (95 % CI = 0.13, 0.92). Among HIV-positive women, CD4 count <200cells/mm3 was associated with recurrence, adjusted OR = 5.47 (95 % CI = 1.24, 24.18). Recurrence of VIA or VILI positive lesions after thermo-coagulation occurs in a significant proportion of women. HIV-positive women with low CD4 counts are at increased risk of recurrent lesions and may be related to immunosuppression.

1 December 2015 in Cancer Epidemiology
Verified
Journal Article
Closed access
AJAntoine Jaquet
Antoine Jaquet
KOKolawole Michael Odutola
Kolawole Michael Odutola
DEDidier K Ekouevi
Didier K Ekouevi
ATAristophane Tanon
Aristophane Tanon
EOEmmanuel Oga
Emmanuel Oga
FDFrancois Dabis
Francois Dabis